The S. pombe translation initiation factor eIF4G is Sumoylated and associates with the SUMO protease Ulp2

SUMO is a small post-translational modifier, that is attached to lysine residues in target proteins. It acts by altering protein-protein interactions, protein localisation and protein activity. SUMO chains can also act as substrates for ubiquitination, resulting in proteasome-mediated degradation of...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 9; no. 5; p. e94182
Main Authors Jongjitwimol, Jirapas, Feng, Min, Zhou, Lihong, Wilkinson, Oliver, Small, Lauren, Baldock, Robert, Taylor, Deborah L, Smith, Duncan, Bowler, Lucas D, Morley, Simon J, Watts, Felicity Z
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 12.05.2014
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:SUMO is a small post-translational modifier, that is attached to lysine residues in target proteins. It acts by altering protein-protein interactions, protein localisation and protein activity. SUMO chains can also act as substrates for ubiquitination, resulting in proteasome-mediated degradation of the target protein. SUMO is removed from target proteins by one of a number of specific proteases. The processes of sumoylation and desumoylation have well documented roles in DNA metabolism and in the maintenance of chromatin structure. To further analyse the role of this modification, we have purified protein complexes containing the S. pombe SUMO protease, Ulp2. These complexes contain proteins required for ribosome biogenesis, RNA stability and protein synthesis. Here we have focussed on two translation initiation factors that we identified as co-purifying with Ulp2, eIF4G and eIF3h. We demonstrate that eIF4G, but not eIF3h, is sumoylated. This modification is increased under conditions that produce cytoplasmic stress granules. Consistent with this we observe partial co-localisation of eIF4G and SUMO in stressed cells. Using HeLa cells, we demonstrate that human eIF4GI is also sumoylated; in vitro studies indicate that human eIF4GI is modified on K1368 and K1588, that are located in the C-terminal eIF4A- and Mnk-binding sites respectively.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: The authors have declared that no competing interests exist.
Conceived and designed the experiments: FZW SJM DLT. Performed the experiments: JJ MF LZ OW LS RB DS LDB FZW DLT. Analyzed the data: MF DS LDB SJM FZW. Contributed reagents/materials/analysis tools: JJ MF LZ LS RB DS LDB SJM FZW. Wrote the paper: FZW SJM.
Current address: Genome Institute of Singapore, Genome, #02-01, Singapore, Singapore
Current address: Centre for Biomedical and Health Science Research, School of Pharmacy and Biomolecular Sciences, University of Brighton, Brighton, United Kingdom
Current address: School of Biochemistry, Clifton, Bristol, United Kingdom
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0094182